Literature DB >> 26885224

Extramedullary relapse in lumbar spine of patient with acute promyelocytic leukemia after remission for 16 years: a case report and literature review.

Zhengmei He1, Shandong Tao1, Yuan Deng1, Yue Chen1, Lixiao Song1, Banghe Ding1, Kankan Chen1, Liang Yu1, Chunling Wang1.   

Abstract

Acute promyelocytic leukemia (APL) is a common myeloid leukemia. At the newly diagnosed stage, it can be fatal because of the serious complication-disseminated intravascular coagulation. With the advent and early application of all-trans retinoic acid, most APL patients can achieve a long-term survival, and only a minority of patients will develop extramedullary relapse after remission. The most common site of extramedullary relapse is central nervous system, while other sites are relatively rare. Here, we report a particularly rare APL patient who experienced extramedullary relapse with lumbar spine as the isolated site after a rather long time of remission for 16 years. At the time of relapse, the main clinical manifestations of the patient are obvious low back pain, weakness in lower limbs and limitation of activity. After treatment of local radiotherapy combined with ATRA and arsenic trioxide, the patient achieved and maintained a second complete remission by now.

Entities:  

Keywords:  Acute promyelocytic leukemia; case report; extramedullary relapse; lumbar spine; review

Year:  2015        PMID: 26885224      PMCID: PMC4730010     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

1.  Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.

Authors:  Kazuyuki Shigeno; Kensuke Naito; Naohi Sahara; Miki Kobayashi; Satoki Nakamura; Sinya Fujisawa; Kaori Shinjo; Akihiro Takeshita; Ryuzo Ohno; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 2.  CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.

Authors:  Lisa D Burry; Jack T Seki
Journal:  Ann Pharmacother       Date:  2002-12       Impact factor: 3.154

3.  Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Authors:  Pau Montesinos; Chelo Rayón; Edo Vellenga; Salut Brunet; José González; Marcos González; Aleksandra Holowiecka; Jordi Esteve; Juan Bergua; José D González; Concha Rivas; Mar Tormo; Vicente Rubio; Javier Bueno; Félix Manso; Gustavo Milone; Javier de la Serna; Inmaculada Pérez; Manuel Pérez-Encinas; Isabel Krsnik; Josep M Ribera; Lourdes Escoda; Bob Lowenberg; Miguel A Sanz
Journal:  Blood       Date:  2010-12-08       Impact factor: 22.113

Review 4.  Treatment of relapsed or refractory acute promyelocytic leukemia.

Authors:  Martin S Tallman
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

5.  Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia--the occurrence of retinoic acid syndrome is a risk factor.

Authors:  B S Ko; J L Tang; Y C Chen; M Yao; C H Wang; M C Shen; H F Tien
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

6.  Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.

Authors:  G Specchia; F Lo Coco; M Vignetti; G Avvisati; P Fazi; F Albano; F Di Raimondo; B Martino; F Ferrara; C Selleri; V Liso; F Mandelli
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

7.  Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.

Authors:  Pau Montesinos; Joaquín Díaz-Mediavilla; Guillermo Debén; Virginia Prates; Mar Tormo; Vicente Rubio; Inmaculada Pérez; Isolda Fernández; Maricruz Viguria; Chelo Rayón; José González; Javier de la Serna; Jordi Esteve; Juan M Bergua; Concha Rivas; Marcos González; Jose D González; Silvia Negri; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia.

Authors:  Francesca Patriarca; Carla Filì; Antonella Geromin; Alessandra Sperotto; Simonetta Prosdocimo; Renato Fanin
Journal:  Eur J Haematol       Date:  2002-05       Impact factor: 2.997

Review 9.  Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.

Authors:  R Ohno; N Asou; K Ohnishi
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.

Authors:  Toru Kiguchi; Yuta Yoshino; Bo Yuan; Seiichiro Yoshizawa; Toshihiko Kitahara; Daigo Akahane; Moritaka Gotoh; Toshikazu Kaise; Hiroo Toyoda; Kazuma Ohyashiki
Journal:  Leuk Res       Date:  2009-09-04       Impact factor: 3.156

View more
  1 in total

1.  Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review.

Authors:  Xuemei Shu; Qiuling Wu; Tao Guo; Hua Yin; Jingdi Liu
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.